CASE REPORT

Rare incidence of non-secretory myeloma with talaromycosis: a case report

Haiting Qin1,2, Ye Qiu1,2, Yanmei Huang1, Mianluan Pan1, Dong Lan1,2, Wen Zeng1,2 and Jianquan Zhang1*

Abstract

Background: Talaromyces marneffei (TM) primarily infects patients with co-morbidities that cause immunodeficiency, but non-secretory myeloma (NSMM) is rare. TSM and NSMM are associated with fever, osteolysis, and swollen lymph nodes, thereby making it difficult for clinicians to make differential diagnosis. In this case, we describe TM infection coexisting with NSMM.

Case presentation: We retrospectively reviewed the case of a male (without human immunodeficiency virus infection) with fever, thoracalgia, swollen lymph nodes, and subcutaneous nodules who presented to the First Affiliated Hospital of Guangxi Medical University in February 2014. Chest computed tomography revealed patchy infiltration and positron emission tomography/computed tomography showed increased metabolic activity in the lower-right lung, lymph nodes, left ninth rib, and right ilium. Pathological examination of the lung, lymph nodes, subcutaneous nodules, and bone marrow showed no malignancy; he was diagnosed with community-acquired pneumonia. His clinical symptoms did not improve after anti-bacterial, anti-Mycobacterium tuberculosis, and anti-non-M. tuberculosis treatment. Later, etiological culture and pathological examination of the subcutaneous nodule proved TM infection, and the patient was re-diagnosed with disseminated TSM, which involved the lungs, lymph nodes, skin, bone, and subcutaneous tissue. After antifungal treatment, the patient showed significant improvement, except for the pain in his bones. Imaging showed aggravated osteolysis, and bone marrow biopsy and immunohistochemistry indicated NSMM. Thus, we conclusively diagnosed the case as NSMM with TSM (involving the lungs, lymph nodes, skin, and subcutaneous tissue). His condition improved after chemotherapy, and he was symptom-free for 7 years.

Conclusion: TM infection is rare in individual with NSMM. Since they have clinical manifestation in common, easily causing misdiagnosis and missed diagnosis, multiple pathological examinations and tissue cultures are essential to provide a differential diagnosis.

Keywords: Talaromyces marneffei, Non-secretory myeloma, Talaromycosis, Human immunodeficiency virus, Case report

Background

Talaromycosis (TSM) is an invasive systemic fungal infection caused by Talaromyces marneffei (TM) around the skin, lymph nodes, lung, liver, bone, and bone marrow, which generally manifests as fever, cough, dyspnea, weight loss, skin and soft tissue lesions, hepatosplenomegaly, lymphadenopathy, and osteolysis. TM primarily infects patients with human immunodeficiency virus (HIV). However, in recent years, we have seen an increase in the number of TM-infected HIV-negative patients [1]. HIV-negative patients infected with TM are associated with co-morbidities, such as hematological malignancies, connective tissue disease, and diabetes mellitus [1, 2]. Non-secretory myeloma (NSMM) is a rare subtype (2–4%) within the multiple myeloma (MM) group

*Correspondence: jqzhang2002@sina.com
1 Department of Respiratory Medicine, The Eighth Affiliated Hospital, Sun Yat Sen University, Shenzhen 518000, Guangdong, China
Full list of author information is available at the end of the article

© The Author(s) 2021. Open Access. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
of hematological malignancies. MM and NSMM share clinical and radiological features, both are characterized by osteolysis, anemia, hypercalcemia, and renal insufficiency; fever and swollen lymph nodes are also common. However, patients with NSMM exhibit normal serum and urine electrophoretic profiles [3]. Individuals with myeloma often present with opportunistic infections, but TM infection is rare. Both MM and TSM can manifest as fever, swollen lymph nodes, and osteolysis, which leads to misdiagnosis or missed diagnosis, resulting in a delay in treatment. In this report, we have described the clinical progression and treatment of a rare case of NSMM with TM infection in an HIV-negative patient.

Case presentation
A 51-year-old man presented with a 2-year history of intermittent fever, thoracalgia, swollen lymph nodes, and subcutaneous nodules and was admitted to the First Affiliated Hospital of Guangxi Medical University in February 2014. His medical, family, and psychosocial history including relevant genetic information had no special. On examination, he exhibited a maximum body temperature of 38.2 °C and multiple swollen lymph nodes, painful nodules were found in the right subclavicular region and left chest wall. Routine blood examination revealed an elevated leukocyte count of $25.43 \times 10^9$ cells/L, a neutrophil count of $19.21 \times 10^9$ cells/L, a lymphocyte count of $3.27 \times 10^9$ cells/L, a platelet number of $642.60 \times 10^9$/L, and a decreased hemoglobin level of 8.72 g/dL. The erythrocyte sedimentation rate was 65 mm/h, and C-reactive protein levels were 136.67 mg/L. The patient’s serum albumin level was 32.8 g/L. The level and rate of clearance of creatinine were 109 μmol/L and 45 mL/min, respectively. The serum IgG level was slightly elevated at 21.420 g/L, whereas IgA and IgM levels were normal. HIV autoantibodies were not detected. Serum and urine immunofixation electrophoresis were negative for monoclonal immunoglobulins. Tumor biomarkers were within their normal range. Computed tomography (CT) of the chest revealed a patchy dense shadow, suggesting left pleural effusion. Positron emission tomography/CT showed increased metabolic activity in the right lower lung, ninth rib on the left, and right ilium and multiple lymph nodes (right subclavicular region, mediastinum, and hilum) (Fig. 1c–e, j). Pathological examination of the lung, lymph nodes, subcutaneous nodule, and bone marrow (right ilium) showed no malignancy. Analysis of the lymph nodes and nodule revealed chronic purulent inflammation. Thus, he was diagnosed with community-acquired pneumonia (not excluding malignancy). He was administered anti-bacterial (cef-tazidime for 5 days), anti-\textit{Mycobacterium tuberculosis}
(combination of isoniazid, rifampicin, pyrazinamide, and ethambutol for 2 weeks), and anti-non-\textit{Mycobacterium tuberculosis} (clarithromycin + rifampin + ethambutol, for 10 days) therapy. However, his condition worsened, and he presented with multiple subcutaneous nodules with yellow secretion from the ulceration in the inguinal region and left thigh (Table 1).

Pathological examination of subcutaneous nodules indicated that microorganisms were located outside the cells of the tissue with a round, oval or sausage-like shape, after periodic acid-Schiff staining, the microorganisms arranged in a mulberry-like shape, and a characteristic diaphragm with a sausage-like fungus could be seen under the microscope at a 400-fold magnification by periodic acid-Schiff stain (Fig. 2). Then, we cultured the secretion from the subcutaneous nodules and observed the growth of a dimorphic pathogen on Sabouraud dextrose agar at 25 °C and 37 °C. At 25 °C, the microorganisms was a mold, growing as yellow-green colony and producing soluble red pigments that diffused into the agar, making the reverse side appear either pink or red (Fig. 3a). The microorganisms grew as a white yeast-like colony with radial stripes in the middle at 37 °C (Fig. 3b). The patient was re-diagnosed with disseminated TSM involving the lungs, lymph nodes, skin, bone, and subcutaneous tissue. He accepted fluconazole (400 mg/day, for 5 days) treatment at the beginning, but his symptoms were not relieved. His overall condition, except for the bone pain, improved after the antifungal amphotericin B treatment (starting at 10 mg/day, gradually increasing to 25 mg/day, for 2 weeks until the patient was discharged). Chest CT showed bone damage and cavities in the bone marrow of multiple ribs, clavicle, acromion and clavicle (Fig. 1f, g, i). Emission CT (ECT) showed a significant increase in the radioactive concentration of technetium-99 m-labeled bisphosphonates in the bilateral clavicles, sternum, multiple ribs, multiple vertebrae, inferior angle of the right scapula, pelvis, and long bones of the limbs, resulting in a dense morphology (Fig. 4a). Owing to the presence of osteolysis, we re-examined the bone marrow of the right ilium. Bone marrow smears suggested reactive hyperplasia and reduction in erythrocyte ratio. Bone marrow biopsy showed the presence of neoplastic cells with eccentric and prominent nucleoli in the bone marrow cavity (Fig. 5a). The cells exhibited abnormal morphology, having a small and round or spindle shape (Fig. 5a). Immunohistochemistry showed the expression of CD38 (Fig. 5b), CD138 (Fig. 5c), and kappa (Fig. 5d) and lambda (Fig. 5e) light chains which were consistent with the diagnosis of plasma cell myeloma. We conclusively diagnosed the patient with NSMM and disseminated TSM (in the lungs, lymph nodes, skin, and subcutaneous tissue). The patient was negative for TM infection and did not complain of bone pain after a year of chemotherapy (bortezomib, lenalidomide, and dexamethasone). ECT re-examination in 2017 showed

### Table 1 Laboratory results

| Test                        | Value      |
|-----------------------------|------------|
| Leukocytes (x 10^9 cells/L) | 25.43      |
| Neutrophils (x 10^9 cells/L)| 19.21      |
| Lymphocytes (x 10^9 cells/L)| 3.27       |
| Hemoglobin (g/dL)           | 8.72       |
| Platelets (x 10^9/L)        | 642.60     |
| Erythrocyte sedimentation rate (mm/h) | 65 |
| C-reactive protein (mg/L)   | 136.67     |
| Albumin (g/L)               | 32.8       |
| Globulin (g/L)              | 35.9       |
| Aspartate aminotransferase (U/L) | 58 |
| Alanine aminotransferase (U/L) | 43 |
| Creatinine (mol/L)          | 109        |
| Creatinine clearance (mL/min)| 45        |
| Immunoglobulin G (g/L)      | 21.420     |
| Immunoglobulin A (g/L)      | 3.809      |
| Immunoglobulin M (g/L)      | 1.005      |
| Percentage of CD4+ (%)      | 39.2       |
| Percentage of CD8+ (%)      | 31.3       |

*Reference ranges: leukocytes, 3.5–9.5 x 10^9 cells/L; neutrophils, 1.8–6.3 x 10^9 cells/L; lymphocytes, 1.1–3.2 x 10^9 cells/L; platelets, 125–350 x 10^9/L; hemoglobin, 13–17.5 g/dL; erythrocyte sedimentation rate, 0–15 mm/h; C-reactive protein levels, < 10 mg/L; creatinine, 59–104 µmol/L; Creatinine clearance, 85–125 mL/min; albumin, 40–55 g/L; globulin, 20–40 g/L; aspartate aminotransferase, 15–45 U/L; alanine aminotransferase, 9–60 U/L; immunoglobulin G, 8–18 g/L; immunoglobulin A, 0.9–4.5 g/L; immunoglobulin M, 0.84–1.32 g/L; percentage of CD4+, 30–46%; percentage of CD8+, 19.2–33.6%*
a reduction in the radioactive content in primary bones (Fig. 4b).

**Discussion and conclusions**

Recent studies have shown that an increasing population of TM-infected HIV-negative individuals have co-morbidities and are immunocompromised [1]. Hematological malignancies are cause by malignant cells and/or immunosuppressive therapy that enables severe immunodeficiency, easily causing opportunistic infections. For NSMM, plasma cells secrete soluble immune active molecules, spontaneously synthesize immunoglobulins without immune activity, and induce abnormal function in B, T, dendritic, and natural killer cells, thereby
hindering the immune response in the body [4]. Traditional or novel chemotherapeutics damage the bone marrow, resulting in granulocytopenia and impaired immune function. So, myeloma patients are usually prone to opportunistic infections, mostly bacterial and viral ones, *Aspergillus, Candida albicans, Candida parapsilosis*, and *Scedosporium prolificans* infections have been reported [5], but TM infection is extraordinarily rare.

Symptoms associated with NSMM and TSM include fever, osteolysis, and swollen lymph nodes. Such patients present with osteolysis throughout the body that can be detected as well-defined lesions in imaging [6, 7]. Swollen lymph nodes are commonly found in patients with TSM and NSMM (upon extramedullary infiltration). Thus, it is difficult to differentially diagnose patients with NSMM and TM infection owing to the similarities in clinical manifestation and imaging, especially when the patient has swollen lymph nodes and/or osteolysis. We concluded that lung cancer in our patient could not be excluded, which was based on the multiple osteolysis observed during imaging. After TM infection was confirmed, we missed NSMM since the repeated pathological examination of the bone marrow showed no malignancy. Moreover, MM and TSM have similar serum globulin profiles; MM enhances the production of immunoglobulins, similar to TSM, especially that of IgG [8]. However, patients with NSMM do not exhibit heightened levels of the M-protein. For TSM patients presenting with multiple osteolysis and/or swollen lymph nodes, hematologic malignancies should be considered if active antifungal therapy proves to be ineffective. For patients with cancer, such as hematological malignancies and lung cancer [9], the presence of TM should be ascertained before or after chemotherapy. The final diagnosis primarily relies on multiple pathological examinations and the pathogenic culture of lymph nodes and bone marrow tissue.

The biopsy of lymph nodes in HIV-negative patients with TSM primarily exhibit granulomatous and purulent inflammation [10]. Granulomatous inflammation involves the presence of numerous epithelioid cells and multinucleated macrophages without caseous necrosis. Purulent inflammation is characterized by numerous neutrophils and macrophages involved in the phagocytosis of the fungus with varying degree of tissue necrosis and abscess. Hematoxylin and eosin staining showed pale blue granules in the fungal cytoplasm. Periodic acid-Schiff or Wright–Giemsa staining revealed of clustered or scattered fungi in the lymphoid tissues; the fungi are distributed in or free from macrophages [11]. Culture of lymph node tissues was performed on Sabouraud dextrose agar, TM was grown at 25 ºC and 37 ºC. At 25 ºC, TM produced a soluble red pigment that diffuses into the agar. At 37 ºC, it resembled yeast-like growth with a spherical, oval, or sausage-like form and a characteristic transverse septum in the middle [12]. In general, pathological examination of lymph nodes in patients with NSMM shows the destruction of the node architecture without inflammatory cell infiltration, which is replaced by a major population
of myeloma plasma cells. Bone marrow smears from patients with TSM show the presence of actively proliferating cells. TM-specific staining shows the presence of the fungus in or outside macrophages. Bone marrow cultures may be positive for TM. Bone marrow smears and biopsies from patients with NSMM show a large number of myeloma plasma cells with enlarged eccentric nuclei. Immature plasma cells have mono-, poly-, or segmented nuclei with prominent nuclei [13].

Since TM infection is rarely found in patients with NSMM, there is no standardized treatment. Thus, it is imperative to devise novel efficacious therapeutic strategies. Therapy of HIV-negative TSM patients with osteolysis is long, patients frequently relapse [7], or new osteolysis appears. The current treatment of HIV-positive TSM patients involves amphotericin B (0.7–1 mg/kg/day for 2 weeks) followed by intracam-azole (200 mg twice daily for 10 weeks) [14]. For newly diagnosed myeloma patients, the National Comprehensive Cancer Network recommends that, regardless of transplantation, the VRD (bortezomib/lenalidomide/dexamethasone combination therapy) chemotherapeutic regimen can improve tolerability and efficacy [15]. Myeloma treatment requires long-term chemotherapy. However, most chemotherapeutics result in immunosuppression and enhance the risk of opportunistic infections. Therefore, the duration of chemotherapy should be tailored for patients based on the presence of TSM. Chemotherapy suppresses immune function, thereby aggravating the infection. Thus, for TM infected patients with malignant tumors that are not in remission, choosing the time of chemotherapy is important. We have noticed that antifungal therapy followed by the VRD regimen in newly diagnosed myeloma patients with TM infection proves to be more effective in controlling symptoms. During treatment, symptoms should be carefully monitored to determine the recurrence of TSM or progression of myeloma.

Abbreviations
NSMM: Non-secretory myeloma; TSM: Talaromyces; TM: Talaromyces marneffei; HIV: Human immunodeficiency virus; MM: Multiple myeloma; CT: Computed tomography; ECT: Emission CT; Ig: Immunoglobulin.

Acknowledgements
None.

Authors’ contributions
HQ, YQ, MP, WZ, and JZ wrote the draft of the manuscript. YH and DL collated the figures for imaging and pathological examinations. JZ was also accountable for all aspects of the work. All authors read and approved the final manuscript.

Funding
This work was supported by the National Natural Science Foundation of China (Grant No. 2015GNXSFAAA139189). The funding bodies had no role in designing the study, in processing the data, and in writing the manuscript.

Availability of data and materials
All data generated or analyzed during this study are included in this published article.

Declarations

Ethics approval and consent to participate
This study was approved by the Ethics Committee associated with the Faculty of Medicine at The First Affiliated Hospital of Guangxi Medical University [Approval No. 2020(KY-E-088)]. The patient received an explanation regarding the study’s objectives in his own language, and written informed consent was obtained from the patient for publication of this case report and any accompanying images.

Consent for publication
Written informed consent was obtained from the patient for publication of accompanying images or other personal or clinical details. A copy of the written consent is available for review by the Editor of this journal.

Competing interests
All authors declare no competing interests.

Author details
1 Department of Respiratory Medicine, The Eighth Affiliated Hospital, Sun Yat Sen University, Shenzhen 518000, Guangdong, China. 2 Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi, China.

Received: 27 August 2020 Accepted: 31 August 2021
Published online: 16 September 2021

References
1. Chan JF, Lau SK, Yuen KY, Woo PC. Talaromyces (Penicillium) marneffei infection in non-HIV-infected patients. Emerg Microb Infect. 2016;5:e19.
2. Qiu Y, Liao H, Zhang J, Zhang X, Tang C, Sun D. Differences in clinical characteristics and prognosis of Penicilliosis among HIV-negative patients with or without underlying disease in Southern China: a retrospective study. BMC Infect Dis. 2015;15:525.
3. Lonia S, Kaufman JL. Non-secretory myeloma: a clinician’s guide. Oncology (Williston Park, NY). 2013;27(9):924–8, 930.
4. Pratt G, Goodyear O, Moss P. Immunodeficiency and immunotherapy in multiple myeloma. Br J Haematol. 2007;138(5):563–79.
5. Teh BW, Teng JC, Urbaniczky C, Grigg A, Harrison SJ, Worth LJ, Slavin MA, Thursky KA. Invasive fungal infections in patients with multiple myeloma: a multi-center study in the era of novel myeloma therapies. Haematologica. 2015;100(1):e28-31.
6. Dimopoulos M, Terpos E, Comenzo RL, Tosi P, Bekacis M, Seizer Q, Siegel D, Lokhorst H, Kumar S, Rajkumar SV, et al. International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple myeloma. Leukemia. 2009;23(9):1545–56.
7. Qiu Y, Zhang J, Liu G, Zhong X, Deng J, He Z, Jing B. Retrospective analysis of 14 cases of disseminated Penicillium marneffei infection with osteolytic lesions. BMC Infect Dis. 2015;15:47.
8. Wong SY, Wong KH, Hui WT, Lee SS, Lo JYC, Cao L, Yuen KY. Differences in clinical and laboratory diagnostic characteristics of Penicilliosis marneffei in human immunodeficiency virus (HIV)- and non-HIV-infected patients. J Clin Microbiol. 2001;39(12):4535–40.
9. Lin F, Qiu Y, Zeng W, Liang Y, Zhang J. Talaromyces marneffei infection in a lung cancer patient: a rare case report. BMC Infect Dis. 2019;19(1):336.
10. Zeng W, Qiu Y, Lu D, Zhang J, Zhong X, Liu G. A retrospective analysis of 7 human immunodeficiency virus-negative infants infected by Penicillium marneffei. Medicine. 2015;94(34):e1439.
11. Chawwin B, Khunamornpong S, Sirivanichai C, Rangdaeng S, Supparatpinyo K, Settakorn J, Ya-i-n C, Thorns R, Phumphudaphap due to Penicil- lium marneffei infection: diagnosis by fine needle aspiration cytology. Mod Pathol. 2002;15(9):939–43.
12. Pan M, Qiu Y, Zeng W, Tang S, Feng X, Deng J, Wei X, He Z, Zhang J. Talaromycosis-associated secondary hemophagocytic lymphohistiocytosis in nine human immunodeficiency virus-negative patients: a multicenter retrospective study. Infect Drug Resist. 2019;12:3807–16.

13. Kumar PV, Owji SM, Talei AR, Malekhusseini SA. Extramedullary plasmacytoma. Fine needle aspiration findings. Acta Cytol. 1997;41(2):364–8.

14. Le T, Kinh NV, Cuc NT, Tung NLN, Lam NT, Thuy PTT, Cuong DD, Phuc PTH, Vinh VH, Hanh DTH, et al. A trial of itraconazole or amphotericin B for HIV-associated talaromycosis. N Engl J Med. 2017;376(24):2329–40.

15. Kumar SK, Callander NS, Alsina M, Atanackovic D, Biermann JS, Castillo J, Chandler JC, Costello C, Faiman M, Fung HC, et al. NCCN guidelines insights: multiple myeloma, version 3.2018. J Natl Compr Cancer Netw. 2018;16(1):11–20.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.